{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:58:00Z","timestamp":1791302280180,"version":"4.1.0"},"reference-count":51,"publisher":"American Chemical Society (ACS)","issue":"39","license":[{"start":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:00:00Z","timestamp":1789776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004901","name":"Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-01945-21"],"award-info":[{"award-number":["APQ-01945-21"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["APQ-02334-24"],"award-info":[{"award-number":["APQ-02334-24"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004901","name":"Funda??o de Amparo ? Pesquisa do Estado de Minas Gerais","doi-asserted-by":"publisher","award":["BPD-00173-22"],"award-info":[{"award-number":["BPD-00173-22"]}],"id":[{"id":"10.13039\/501100004901","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico","doi-asserted-by":"publisher","award":["308785\/2023-1"],"award-info":[{"award-number":["308785\/2023-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient?fico e Tecnol?gico","doi-asserted-by":"publisher","award":["406193\/2025-8"],"award-info":[{"award-number":["406193\/2025-8"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004809","name":"Financiadora de Estudos e Projetos","doi-asserted-by":"publisher","award":["01.24.0627.00"],"award-info":[{"award-number":["01.24.0627.00"]}],"id":[{"id":"10.13039\/501100004809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005672","name":"Funda??o de Apoio ao Desenvolvimento do Ensino, Ci?ncia e Tecnologia do Estado de Mato Grosso do Sul","doi-asserted-by":"publisher","award":["TO 123\/2024"],"award-info":[{"award-number":["TO 123\/2024"]}],"id":[{"id":"10.13039\/501100005672","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena??o de Aperfei?oamento de Pessoal de N?vel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Dasatinib (DAS) is a biopharmaceutical classification system (BCS) class II drug that is used orally to treat chronic myelogenous leukemia. However, its very low and pH-dependent aqueous solubility severely limits its oral bioavailability. To address this biopharmaceutical limitation, we designed more soluble multicomponent crystalline forms (MCCs) of DAS. Two novel salt solvate forms were successfully obtained via solvent evaporation through reactions with maleic and fumaric acids. A comprehensive solid-state evaluation of these salt solvate forms was conducted by using X-ray diffraction (SCXRD, PXRD), spectroscopy (FT-IR and 1H NMR), and thermal (TG and DSC) analyses. Both MCCs of DAS have displayed substantial enhancements in buffered aqueous solubility (up 1470-fold) and intrinsic dissolution rate (up 312-fold) compared with the parent drug. Furthermore, the DAS MCCs exhibited an increased cytotoxicity and selectivity toward tumor cells. These fulfillments highlight the potential of crystalline salt engineering to enhance the unsatisfactory oral bioavailability and anticancer efficacy of the DAS.<\/jats:p>","DOI":"10.1021\/acsomega.6c01923","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:01:36Z","timestamp":1789833696000},"page":"58686-58697","source":"Crossref","is-referenced-by-count":0,"title":["Fast-Dissolving\nand Highly Soluble Dasatinib Multicomponent\nCrystals Efficiently Inhibit Leukemia Cell Viability"],"prefix":"10.1021","volume":"11","author":[{"given":"Luan F.","family":"Diniz","sequence":"first","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz C. G.","family":"Dio\u0301genes","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-9155","authenticated-orcid":true,"given":"Paulo S.","family":"Carvalho Jr","sequence":"additional","affiliation":[{"name":"Universidade Federal do Mato Grosso do Sul , , , ,","place":["Campo Grande, MS, Brazil, 79074-460"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezequiel A. D.","family":"Junior","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6358-4806","authenticated-orcid":true,"given":"Alexia D.","family":"Nascimento","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]},{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0560-8491","authenticated-orcid":true,"given":"Maria E.","family":"Corte\u0301s","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]},{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7656-1849","authenticated-orcid":true,"given":"Rube\u0301n Dario","family":"Sinisterra","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]},{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9042-9094","authenticated-orcid":true,"given":"Renata","family":"Diniz","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3905-3674","authenticated-orcid":true,"given":"Christian","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais , , , ,","place":["Belo Horizonte, MG, Brazil, 31270-901"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,19]]},"reference":[{"issue":"7","key":"2026100610482898300_cit1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.addr.2007.05.010","article-title":"Salt\nFormation to Improve Drug Solubility","volume":"59","author":"Serajuddin","year":"2007","journal-title":"Adv. Drug\nDelivery Rev."},{"key":"2026100610482898300_cit2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2017.03.003","article-title":"Pharmaceutical Cocrystals,\nSalts and Multicomponent\nSystems; Intermolecular Interactions and Property Based Design","volume":"117","author":"Berry","year":"2017","journal-title":"Adv. Drug Delivery Rev."},{"issue":"7","key":"2026100610482898300_cit3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.addr.2007.05.011","article-title":"Crystal Engineering\nof Active Pharmaceutical Ingredients to Improve Solubility and Dissolution\nRates","volume":"59","author":"Blagden","year":"2007","journal-title":"Adv. Drug Delivery Rev."},{"issue":"95","key":"2026100610482898300_cit4","doi-asserted-by":"publisher","first-page":"14052","DOI":"10.1039\/D3CC04313D","article-title":"Crystal Engineering:\nFrom Promise to Delivery","volume":"59","author":"Braga","year":"2023","journal-title":"Chem. Commun."},{"issue":"13","key":"2026100610482898300_cit5","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1021\/acs.chemrev.1c00987","article-title":"Crystal\nEngineering of Pharmaceutical\nCocrystals in the Discovery and Development of Improved Drugs","volume":"122","author":"Bolla","year":"2022","journal-title":"Chem. Rev."},{"issue":"3","key":"2026100610482898300_cit6","doi-asserted-by":"publisher","first-page":"355","DOI":"10.15171\/apb.2018.042","article-title":"A Review about Regulatory\nStatus\nand Recent Patents of Pharmaceutical Co-Crystals","volume":"8","author":"Kumar","year":"2018","journal-title":"Adv. Pharm. Bull."},{"issue":"4","key":"2026100610482898300_cit7","doi-asserted-by":"publisher","first-page":"479","DOI":"10.15171\/apb.2016.062","article-title":"Pharmaceutical Cocrystals: Regulatory and Strategic\nAspects, Design and Development","volume":"6","author":"Gadade","year":"2016","journal-title":"Adv. Pharm.\nBull."},{"issue":"1","key":"2026100610482898300_cit8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jpp\/rgad097","article-title":"Pharmaceutical Co-Crystals:\nA Green Way to Enhance Drug Stability and Solubility for Improved\nTherapeutic Efficacy","volume":"76","author":"Chettri","year":"2024","journal-title":"J. Pharm. Pharmacol."},{"issue":"36","key":"2026100610482898300_cit9","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1039\/C8CE00707A","article-title":"Pharmaceutical\nCocrystallization:\nAn Effective Approach to Modulate the Physicochemical Properties of\nSolid-State Drugs","volume":"20","author":"Dai","year":"2018","journal-title":"CrystEngComm"},{"issue":"1","key":"2026100610482898300_cit10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ijpharm.2012.11.028","article-title":"Use\nof Pharmaceutical Salts and Cocrystals\nto Address the Issue of Poor Solubility","volume":"453","author":"Elder","year":"2013","journal-title":"Int.\nJ. Pharm."},{"issue":"4","key":"2026100610482898300_cit11","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1039\/C5CC08216A","article-title":"Pharmaceutical\nCocrystals: Along the Path to Improved Medicines","volume":"52","author":"Duggirala","year":"2016","journal-title":"Chem. Commun."},{"issue":"8","key":"2026100610482898300_cit12","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s11095-024-03748-5","article-title":"Multi-Component Crystal Strategy\nfor Improving Water Solubility and Antifungal Activity of Climbazole","volume":"41","author":"Song","year":"2024","journal-title":"Pharm. Res."},{"issue":"5","key":"2026100610482898300_cit13","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1021\/acs.cgd.4c01617","article-title":"Multicomponent Solid Forms of Pioglitazone\nand Their\nInfluence on Drug Dissolution","volume":"25","author":"Shimada","year":"2025","journal-title":"Cryst. Growth\nDes."},{"issue":"24","key":"2026100610482898300_cit14","doi-asserted-by":"publisher","first-page":"8693","DOI":"10.3390\/molecules27248693","article-title":"A Review of\nCoformer Utilization in Multicomponent Crystal Formation","volume":"27","author":"Wathoni","year":"2022","journal-title":"Molecules"},{"issue":"11","key":"2026100610482898300_cit15","doi-asserted-by":"publisher","first-page":"5790","DOI":"10.1158\/0008-5472.CAN-05-4187","article-title":"The Structure\nof Dasatinib (BMS-354825) Bound to Activated ABL Kinase Domain Elucidates\nIts Inhibitory Activity against Imatinib-Resistant ABL Mutants","volume":"66","author":"Tokarski","year":"2006","journal-title":"Cancer Res."},{"issue":"6","key":"2026100610482898300_cit16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I Study of the\nEffect of Gastric Acid PH Modulators on the Bioavailability of Oral\nDasatinib in Healthy Subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J. Clin. Pharmacol."},{"issue":"5","key":"2026100610482898300_cit17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1208\/s12249-025-03130-7","article-title":"Dasatinib\nPharmacokinetics and Advanced Nanocarrier Strategies: From Systemic\nLimitations to Targeted Success","volume":"26","author":"Keerikkadu","year":"2025","journal-title":"AAPS PharmSciTech"},{"issue":"7","key":"2026100610482898300_cit18","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical Pharmacokinetics\nand Pharmacodynamics of Dasatinib","volume":"59","author":"Leve\u0302que","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"2026100610482898300_cit19","doi-asserted-by":"publisher","first-page":"100247","DOI":"10.1016\/j.chphi.2023.100247","article-title":"Cocrystallization of Dasatinib with\nDifferent Acids Improves the Solubility and Physicochemical Properties:\nA Combined Experimental and Theoretical Studies","volume":"7","author":"Abdul Azeeze","year":"2023","journal-title":"Chemical Physics Impact"},{"issue":"7","key":"2026100610482898300_cit20","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1021\/acs.oprd.0c00549","article-title":"Insight into the Formation of Heteromolecular\nHydrogen Bonds between Dasatinib and GRAS Molecules","volume":"25","author":"Mondal","year":"2021","journal-title":"Org. Process Res. Dev."},{"issue":"3","key":"2026100610482898300_cit21","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/ijms20030591","article-title":"Dasatinib\/HP-\u03b2-CD\nInclusion Complex Based Aqueous\nFormulation as a Promising Tool for the Treatment of Paediatric Neuromuscular\nDisorders","volume":"20","author":"Cutrignelli","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"2026100610482898300_cit22","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3390\/pharmaceutics14010197","article-title":"Dasatinib\nNanoemulsion and Nanocrystal for Enhanced Oral Drug Delivery","volume":"14","author":"Wang","year":"2022","journal-title":"Pharmaceutics"},{"issue":"11","key":"2026100610482898300_cit23","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.3390\/pharmaceutics14112450","article-title":"Formulation\nCharacterization and Pharmacokinetic Evaluation of Amorphous Solid\nDispersions of Dasatinib","volume":"14","author":"Dharani","year":"2022","journal-title":"Pharmaceutics"},{"key":"2026100610482898300_cit24","doi-asserted-by":"publisher","first-page":"125007","DOI":"10.1016\/j.ijpharm.2024.125007","article-title":"Enhancing Oral Bioavailability\nof Dasatinib via Supersaturable SNEDDS:\nInvestigation of Precipitation Inhibition and IVIVC through in-Vitro\nLipolysis-Permeation Model","volume":"668","author":"Mageshvaran","year":"2025","journal-title":"Int. J. Pharm."},{"issue":"21","key":"2026100610482898300_cit25","doi-asserted-by":"publisher","first-page":"39632","DOI":"10.1016\/j.heliyon.2024.e39632","article-title":"Development, Optimization,\nand Characterization\nof Polymeric Micelles to Improve Dasatinib Oral Bioavailability: Hep\nG2 Cell Cytotoxicity and in Vivo Pharmacokinetics for Targeted Liver\nCancer Therapy","volume":"10","author":"Shaikh","year":"2024","journal-title":"Heliyon"},{"issue":"1","key":"2026100610482898300_cit26","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/21691401.2023.2264358","article-title":"Study on Tumour Cell-Derived Hybrid\nExosomes as Dasatinib Nanocarriers for Pancreatic Cancer Therapy","volume":"51","author":"Zhou","year":"2023","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"issue":"4","key":"2026100610482898300_cit27","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.xphs.2016.01.024","article-title":"Solvates of Dasatinib: Diversity\nand Isostructurality","volume":"105","author":"Sarcevic\u030ca","year":"2016","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"2026100610482898300_cit28","doi-asserted-by":"publisher","first-page":"5014","DOI":"10.1021\/acs.cgd.4c00248","article-title":"Similarity\nand Differences of Dasatinib Solvates: A Crystallographic Perspective","volume":"24","author":"Trimdale-Deksne","year":"2024","journal-title":"Cryst. Growth Des."},{"issue":"8","key":"2026100610482898300_cit29","doi-asserted-by":"publisher","first-page":"7032","DOI":"10.1021\/acsomega.1c06753","article-title":"Stable\nFatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction,\nProcess, and Physicochemical Properties","volume":"7","author":"Saladi","year":"2022","journal-title":"ACS\nOmega"},{"issue":"2","key":"2026100610482898300_cit30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1107\/S0021889808042726","article-title":"OLEX2: A Complete\nStructure Solution, Refinement and Analysis Program","volume":"42","author":"Dolomanov","year":"2009","journal-title":"J. Appl. Crystallogr."},{"issue":"1","key":"2026100610482898300_cit31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1107\/S2053273314026370","article-title":"SHELXT\n- Integrated Space-Group and Crystal-Structure Determination","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr. A"},{"issue":"1","key":"2026100610482898300_cit32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1107\/S2053229614024218","article-title":"Crystal\nStructure Refinement with SHELXL","volume":"71","author":"Sheldrick","year":"2015","journal-title":"Acta Crystallogr.\nC Struct. Chem."},{"key":"2026100610482898300_cit33","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1107\/S2053229614024929","article-title":"PLATON\nSQUEEZE: A Tool for the Calculation of the Disordered Solvent Contribution\nto the Calculated Structure Factors","volume":"71","author":"Spek","year":"2015","journal-title":"Acta Crystallogr.\nC Struct. Chem."},{"key":"2026100610482898300_cit34","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1107\/S1600576719014092","article-title":"Mercury\n4.0: From Visualization to\nAnalysis, Design and Prediction","volume":"53","author":"Macrae","year":"2020","journal-title":"J. Appl. Crystallogr."},{"key":"2026100610482898300_cit35","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1107\/S1600576721002910","article-title":"CrystalExplorer: A Program for Hirshfeld\nSurface Analysis, Visualization and Quantitative Analysis of Molecular\nCrystals","volume":"54","author":"Spackman","year":"2021","journal-title":"J. Appl. Crystallogr."},{"issue":"2","key":"2026100610482898300_cit36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1107\/S2052520616003954","article-title":"The Cambridge Structural\nDatabase","volume":"72","author":"Groom","year":"2016","journal-title":"Acta Crystallogr. B Struct. Sci. Cryst.\nEng. Mater."},{"key":"2026100610482898300_cit37","volume-title":"ICH Topic Q2 (R1) Validation of Analytical\nProcedures","author":"ICH.","year":"2005"},{"issue":"1","key":"2026100610482898300_cit38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jps.20212","article-title":"Comparison of a\nMiniaturized Shake-Flask\nSolubility Method with Automated Potentiometric Acid\/Base Titrations\nand Calculated Solubilities","volume":"94","author":"Glomme","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"2026100610482898300_cit39","volume-title":"ICH Topic Q1B Photostability Testing of New\nActive Substances\nand Medicinal Products Step 5 NOTE FOR GUIDANCE ON THE PHOTOSTABILITY\nTESTING OF NEW ACTIVE SUBSTANCES AND MEDICINAL PRODUCTS","author":"ICH.","year":"1998"},{"issue":"20","key":"2026100610482898300_cit40","doi-asserted-by":"publisher","first-page":"6362","DOI":"10.1039\/c2ce26055g","article-title":"Acid\u2013Base\nCrystalline Complexes and the PKa Rule","volume":"14","author":"Cruz-Cabeza","year":"2012","journal-title":"CrystEngComm"},{"key":"2026100610482898300_cit41","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1039\/D1FD00081K","article-title":"The Role of Solvation\nin Proton Transfer Reactions: Implications for Predicting Salt\/Co-Crystal\nFormation Using the \u0394pKa Rule","volume":"235","author":"Cruz-Cabeza","year":"2022","journal-title":"Faraday\nDiscuss."},{"issue":"4","key":"2026100610482898300_cit42","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1021\/cg300152p","article-title":"Structural and Physicochemical Aspects\nof Dasatinib Hydrate and Anhydrate Phases","volume":"12","author":"Roy","year":"2012","journal-title":"Cryst.\nGrowth Des."},{"issue":"8","key":"2026100610482898300_cit43","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1211\/jpp.61.08.0001","article-title":"Analysis of Solid-State\nTransformations of Pharmaceutical Compounds Using Vibrational Spectroscopy","volume":"61","author":"Heinz","year":"2009","journal-title":"J. Pharm. Pharmacol."},{"key":"2026100610482898300_cit44","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.ejmech.2017.10.058","article-title":"Synthesis Crystal Structure and Biological\nEvaluation of a New Dasatinib Copper(II) Complex as Telomerase Inhibitor","volume":"143","author":"Qin","year":"2018","journal-title":"Eur. J. Med. Chem."},{"issue":"79","key":"2026100610482898300_cit45","doi-asserted-by":"publisher","first-page":"11764","DOI":"10.1039\/C6CC07011F","article-title":"A Bioorthogonal Approach for Imaging\nthe Binding between Dasatinib and Its Target Proteins inside Living\nCells","volume":"52","author":"Kim","year":"2016","journal-title":"Chem. Commun."},{"issue":"12","key":"2026100610482898300_cit46","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1016\/j.xphs.2018.08.010","article-title":"Applications of Powder\nX-Ray Diffraction in Small Molecule Pharmaceuticals: Achievements\nand Aspirations","volume":"107","author":"Thakral","year":"2018","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"2026100610482898300_cit47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to Address Low Drug Solubility\nin Discovery and Development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"issue":"16","key":"2026100610482898300_cit48","doi-asserted-by":"publisher","first-page":"4359","DOI":"10.1158\/1078-0432.CCR-13-0980","article-title":"Contribution of ABCC4-Mediated Gastric\nTransport to\nthe Absorption and Efficacy of Dasatinib","volume":"19","author":"Furmanski","year":"2013","journal-title":"Clin.\nCancer Res."},{"issue":"3","key":"2026100610482898300_cit49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pcrysgrow.2016.07.001","article-title":"Spring and Parachute: How Cocrystals Enhance Solubility","volume":"62","author":"Bavishi","year":"2016","journal-title":"Prog. Cryst. Growth Charact. Mater."},{"issue":"44","key":"2026100610482898300_cit50","doi-asserted-by":"publisher","first-page":"7803","DOI":"10.1039\/d2ce00818a","article-title":"Energy Framework\nand Solubility: A New Predictive Model in the Evaluation of the Structure-Property\nRelationship of Pharmaceutical Solid Forms","volume":"24","author":"Freitas","year":"2022","journal-title":"CrystEngComm"},{"key":"2026100610482898300_cit51","volume-title":"ISO International Organization for Standardization\nBiological of Medical Devices - Part 5","author":"ISO 10993\u20135.","year":"2009"}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.6c01923","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/39\/58686\/68564170\/acsomega.6c01923.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/11\/39\/58686\/68564170\/acsomega.6c01923.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T15:25:02Z","timestamp":1791300302000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/11\/39\/58686\/5433295\/Fast-Dissolving-and-Highly-Soluble-Dasatinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,19]]},"references-count":51,"journal-issue":{"issue":"39","published-online":{"date-parts":[[2026,9,19]]},"published-print":{"date-parts":[[2026,10,6]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.6c01923","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,19]]}}}